PheCheck™ is an investigational device currently in clinical study. It has not been cleared or approved by the FDA and is not available for sale. Participation in the clinical study is limited to enrolled sites.
Built because patients have waited long enough
Aptatek BioSciences is developing HomeCheck™, an aptamer-based platform for home biomarker monitoring. We started with phenylalanine because people living with PKU deserve timely answers that fit into real life, not delayed results that leave them guessing between visits.
Our ORIGIN STORY
From Columbia research to a patient-first company
Aptatek was founded on DNA aptamer technology developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. That scientific foundation opened the door to a portable, quantitative approach to phenylalanine monitoring, and to a company built around a simple belief: diagnostics should better serve patients, caregivers, and clinicians.
OUR mission
Make metabolic monitoring more timely and accessible
Our mission is to bring meaningful biomarker information closer to the people who need it most. We are starting with PKU, where patients and care teams need better visibility between clinic visits, and building toward a platform that can support additional small-molecule monitoring applications over time.
What guides us
Patient-centered. Clinically useful. Built to scale.
Aptatek is designed around the realities of care: the burden of waiting, the need for actionable data, and the importance of fitting into everyday routines. We believe home monitoring should help people make better decisions, support care teams with timely insight, and create a foundation for future applications beyond PKU.
The team
Diagnostics executive with 30+ years of experience leading life sciences companies from development through commercialization, with deep expertise in strategy, operations, growth, and market execution.
Commercial and business development leader with 25+ years of experience across healthtech, diagnostics, medical devices, and biopharma, including commercialization, pharma partnerships, and launch strategy.
Professor of Pathology at Columbia University Medical Center and a clinical expert in inborn errors of metabolism, bringing deep expertise in PKU and metabolic disease care to Aptatek's medical strategy.
Professor of Medicine and Biomedical Engineering at Columbia University and inventor of the DNA aptamer technology underlying PheCheck™, with expertise in molecular recognition, biosensing, and diagnostics.